SYSTM Wealth Solutions LLC Lowers Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

SYSTM Wealth Solutions LLC trimmed its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 35.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 10,188 shares of the company’s stock after selling 5,663 shares during the period. SYSTM Wealth Solutions LLC’s holdings in TransMedics Group were worth $1,535,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its holdings in shares of TransMedics Group by 10.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company’s stock valued at $31,358,000 after purchasing an additional 38,951 shares during the last quarter. Vanguard Group Inc. increased its position in shares of TransMedics Group by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock valued at $147,214,000 after acquiring an additional 50,673 shares in the last quarter. Alpha DNA Investment Management LLC bought a new stake in shares of TransMedics Group during the fourth quarter valued at approximately $500,000. Russell Investments Group Ltd. increased its position in shares of TransMedics Group by 337,462.5% during the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock valued at $1,997,000 after acquiring an additional 26,997 shares in the last quarter. Finally, Hsbc Holdings PLC increased its position in shares of TransMedics Group by 19.0% during the fourth quarter. Hsbc Holdings PLC now owns 41,650 shares of the company’s stock valued at $3,287,000 after acquiring an additional 6,650 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on TMDX shares. Morgan Stanley raised their price target on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Piper Sandler raised their price target on shares of TransMedics Group from $170.00 to $180.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Cantor Fitzgerald began coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 target price for the company. Finally, TD Cowen lifted their target price on shares of TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, June 7th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $171.44.

Insider Activity

In related news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the transaction, the insider now owns 20,843 shares in the company, valued at approximately $3,267,557.11. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction on Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,948,714.31. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the transaction, the insider now owns 20,843 shares in the company, valued at approximately $3,267,557.11. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock valued at $9,650,880 in the last 90 days. Company insiders own 7.00% of the company’s stock.

TransMedics Group Trading Up 3.2 %

Shares of TMDX stock opened at $156.08 on Wednesday. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $177.37. The firm has a fifty day moving average price of $154.40 and a 200-day moving average price of $127.98. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The company has a market cap of $5.21 billion, a price-to-earnings ratio of -459.06 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. During the same quarter in the previous year, the firm posted ($0.03) EPS. The company’s revenue for the quarter was up 117.7% compared to the same quarter last year. As a group, equities analysts predict that TransMedics Group, Inc. will post 1.23 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.